Vimarsana
Biggest News Aggregation in the World

Csl Behring News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Csl Behring. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Csl Behring Today - Breaking & Trending Today

BLOOMBERG Market Makers May 22, 2015 - Vimarsana News

BLOOMBERG Market Makers May 22, 2015

Watch. Erik time for our top stories is one of his best begin with this. German chancellor Angela Merkel is standing out optimism in the greek crisis. They end the night with the leaders of greece in france. Greece once the remaining 8 billion in bailout funds to the void avoid the fall. She says there is a whole lot more to do before that can happen. I will have bilateral talks and have hardly spoken last night with the french president and the greek Prime Minister. It was a very friendly, constructive exchange, but it is clear that further work with the three institutions is necessary. Erik ...

Harris Poll Survey Finds People Receiving Treatment for CIDP Are Interested in Exploring More Convenient Treatment Options - Vimarsana News

Harris Poll Survey Finds People Receiving Treatment for CIDP Are Interested in Exploring More Convenient Treatment Options

/PRNewswire/ -- CSL Behring, a business unit of global biotechnology leader CSL, today announced survey results showing that the majority of surveyed people...

High-Cost Gene Therapies Present Reimbursement, Access Challenges - Vimarsana News

High-Cost Gene Therapies Present Reimbursement, Access Challenges

Investigators propose potential payment models for gene therapies that consider equitable patient access and payer reimbursement.

Source: ajmc.com
Workers Struggles: The Americas - Vimarsana News

Workers Struggles: The Americas

Nonunion dockworkers blocked entrances to Mexico’s Lazaro Cardenas Port while dockers across Chile staged a 72-hour strike and 700 pharmaceutical workers in Illinois have ratified a contract.

Source: wsws.org
UniQure To Sell Royalty Interest In HEMGENIX For Up To $400 Mln - Vimarsana News

UniQure To Sell Royalty Interest In HEMGENIX For Up To $400 Mln

Gene therapy company uniQure N.V. (QURE) announced Monday it has entered into a definitive agreement to sell a portion of the royalty rights due to uniQure from CSL Behring from the net sales of HEMGENIX (etranacogene dezaparvovec-drbl) to HealthCare Royalty (HCRx) and Sagard Healthcare for a gross purchase price of up to $400 million in cash.